Event: EMWA Spring Conference 2026
Date: May 5-8,2026
Location: Barceló Sants Hotel, Barcelona
The European Medical Writers Association was founded in 1989 by a small group of professional biomedical communicators with academic, industrial and journalistic affiliations. EMWA has grown since then and now has over 1,000 members from 39 different countries (including 12 countries outside Europe) and includes academics and professionals working in-house or freelance for pharmaceutical and medical communications companies, research institutes, and in the field of scientific journalism. AlphaLife Sciences is excited to participate and share our insights at the event. We look forward to engaging with you in person!
Booth Number: TBD
Presentation from AlphaLife Sciences (two in total):
The first presentation & panel
Date: May 7
Time: 11:00–12:30 CET
Session Title: Inside the Black Box: Building Trustworthy AI Tools for Medical Writing
Host: Dr Namrata Singh, Founder and CEO, Turacoz
Our Speaker: Mike Liang, Head of AI Product & Strategy, AlphaLife Sciences
Title: Designing Trustworthy AI for Regulatory Medical Writing
This session offers a practice‑oriented look at AI‑powered tool development and the quality assurance mechanisms required for high‑stakes regulatory writing. We will cover three key aspects:
1. Foundational Design for AI Tools: Architecting for Compliance: We examine how developers build and validate AI systems specifically for medical writing tasks to ensure they are “fit for purpose.” This phase explores how medical writers act as advisors during the development stage, setting compliance standards and providing the domain expertise required to guide responsible AI evolution.
2. Co‑piloted Workflow Orchestration: Ensuring Narrative Integrity: We look at AI‑orchestrated authoring across eCTD documents. This stage highlights human‑in‑the‑loop authoring, end‑to‑end review, and automated quality control. We show how “change intelligence” maintains narrative integrity and structural consistency during complex data updates.
3. Quality Verification: Benchmarking Regulatory Readiness: We discuss how to measure regulatory readiness through professional benchmark design and task‑specific performance assessment. We evaluate five pillars of clinical trust: accuracy, completeness, consistency, factuality, and structural traceability.
The session concludes with practical advice on your evolving role as a “scientist in the loop” and on how to upgrade your skills to thrive in an AI‑augmented regulatory landscape.
The Second presentation
Date: May 8
Time: 12:35-13.35 CET
Session: Lunchtime Session
Speaker: Mike Liang, Head of AI Product & Strategy, AlphaLife Sciences
Title: Accelerate Authoring Across R&D Documents: AI Tool Demos for CSR, CTD, Non-Clinical & CMC
This session presents practical approaches to AI-orchestrated authoring and quality control for regulatory and medical writing across the R&D document lifecycle, spanning clinical, non-clinical, quality, safety, labeling, and regulatory submission–related documents.
We demonstrate how teams can work in familiar environments—such as a Microsoft Word add-in and a web portal—while automating up to 90% of first-draft content in alignment with regulatory guidance. The approach streamlines review comment incorporation, document finalization, quality control, and subsequent updates to accelerate submission timelines.
The workflow integrates with enterprise systems, including Veeva RIM, supporting the end-to-end lifecycle of regulatory submissions alongside existing document management and review processes.
Finally, we introduce an R&D document-network model for change intelligence, enabling automated change detection, dependency mapping for impact assessment, visible change lineage, and downstream propagation—supporting cross-document consistency and scalable QC.
To request a meeting, fill out the form provided and a representative will be in contact soon to schedule.
